BMO Capital Markets Reaffirms Outperform Rating for Silence Therapeutics (NASDAQ:SLN)

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “outperform” rating reissued by analysts at BMO Capital Markets in a research report issued on Monday, Marketbeat reports.

Several other research analysts also recently weighed in on the company. Morgan Stanley reiterated an “overweight” rating and set a $49.00 price target on shares of Silence Therapeutics in a research note on Tuesday, October 8th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Jefferies Financial Group started coverage on Silence Therapeutics in a report on Tuesday, September 3rd. They set a “buy” rating and a $40.00 price objective on the stock. Chardan Capital reissued a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $57.20.

Silence Therapeutics Stock Performance

SLN stock opened at $7.67 on Monday. The company has a market capitalization of $229.56 million, a price-to-earnings ratio of -4.89 and a beta of 1.05. Silence Therapeutics has a fifty-two week low of $5.81 and a fifty-two week high of $27.72. The stock has a fifty day moving average of $15.63 and a 200-day moving average of $18.03.

Institutional Trading of Silence Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SLN. SG Americas Securities LLC raised its holdings in shares of Silence Therapeutics by 4,802.8% during the 2nd quarter. SG Americas Securities LLC now owns 343,196 shares of the company’s stock valued at $6,521,000 after buying an additional 336,196 shares in the last quarter. Legato Capital Management LLC purchased a new position in shares of Silence Therapeutics during the 2nd quarter valued at about $376,000. Custom Index Systems LLC purchased a new position in shares of Silence Therapeutics during the 2nd quarter valued at about $282,000. Nicholas Investment Partners LP purchased a new position in shares of Silence Therapeutics during the 2nd quarter valued at about $2,859,000. Finally, First Turn Management LLC purchased a new position in shares of Silence Therapeutics during the 2nd quarter valued at about $10,209,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.